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Abstract
Infections caused by carbapenemase-producing Klebsiella pneumoniae (CPKP) are increasing in frequency worldwide. CPKP isolates exhi-
bit extensive drug resistance phenotypes, complicate therapy, and limit treatment options. Although CPKP isolates are often highly
resistant to carbapenems, a proportion of these have relatively low MICs for carbapenems, raising the question of whether this class of
agents has any therapeutic potential against CPKP infections. Results from animal studies and patient outcome data indicate that carba-
penems retain meaningful in vitro activity against CPKP isolates with carbapenem MICs of £4 mg/L. Accumulating clinical experience also
suggests that the therapeutic efﬁcacy of carbapenems against CPKP isolates with MICs of £4 mg/L is enhanced when these agents are
administered in combination with another active antibiotic. The results of human pharmacokinetic/pharmacodynamic studies are in line
with the above observations; it is highly probable that a high-dose/prolonged-infusion regimen of a carbapenem would attain a time
above the MIC value of 50% for CPKP isolates with MICs up to 4 mg/L, ensuring acceptable drug exposure and favourable treatment
outcome. The analyses summarized in this review support the notion that carbapenems have their place in the treatment of CPKP
infections and that the currently proposed EUCAST clinical breakpoints could direct physicians in making treatment decisions.
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Introduction
Klebsiella pneumoniae is a notorious recipient of resistance
genes, and over the last two decades a number of
resistance mechanisms have accumulated in this pathogen.
Resistance to b-lactams is mainly mediated by extended-
spectrum b-lactamases, with the TEM, SHV and CTX-M
types being predominant [1]. More recently, resistance to
carbapenems, mediated by b-lactamases with carbapenem-
hydrolysing activity (carbapenemases), has emerged. The
most prevalent among these enzymes are the serine carba-
penemases KPC and OXA-48, and the metallo-b-lactamases
VIM, IMP, and NDM [2,3]. Carbapenemase-producing
K. pneumoniae (CPKP) isolates have undergone extensive
dissemination in many countries, and continues to spread in
new geographical locations, indicating an ongoing dynamic
process [4–7].
Certain types of carbapenemases show geographical asso-
ciations. KPC-producing K. pneumoniae isolates were ﬁrst
found in North Carolina, and subsequently emerged in Eur-
ope, Latin America, and China [7–9]. In countries such as
Greece and Israel, and in the eastern USA, KPC-producing
K. pneumoniae isolates have become endemic [8–10]. The
metallo-b-lactamases VIM and IMP are scattered globally,
with VIM predominating in southern Europe and IMP in the
Far East, and NDM being widespread in India and Pakistan
[3,11,12]. OXA-48-producing K. pneumoniae isolates were
ﬁrst described in Turkey, and subsequently emerged in the
Middle East, India, Europe, and North Africa [7,13].
CPKP isolates affect mainly hospitalized patients with
underlying diseases and poor functional status [14–16].
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They often exhibit extensive drug resistance phenotypes,
complicate therapy, and limit treatment options [15–21].
These organisms generally have elevated carbapenem MICs,
but, for some isolates, routine susceptibility testing may
show low MIC values (£4 mg/L) despite the production of
a carbapenemase [16,22–25]. This phenomenon has impor-
tant implications for reporting susceptibility results, and
raises the fundamental question of whether carbapenems
can still be used in the treatment of infections caused by
CPKP isolates with low MICs. In this report, we review the
relevant literature and attempt to give a clinical perspective
on the issue.
Variation of in vitro Susceptibilities of
CPKP Isolates to Carbapenems
Carbapenem MICs for CPKP isolates may vary within a
broad range of values, from 0.12 to >256 mg/L [16,22–25].
This variation depends on both the geographical origin of the
bacterial isolates and the type of carbapenemase produced
[8]. Surprisingly, although VIM enzymes have strong carbape-
nem-hydrolytic activity, a proportion of VIM-producing
K. pneumoniaeisolates have low carbapenem MICs [24–26]. In
a previous report from Greece on 67 VIM-producing
K. pneumoniae isolates, not only did their carbapenem MICs
range from 0.12 to 32 mg/L, but, notably, 53 (79%) isolates
had an MIC of £4 mg/L for at least one carbapenem [26].
Similarly, IMP-producing K. pneumoniae isolates may show
only a small reduction in carbapenem susceptibility. For
example, 15 of 17 IMP-producing K. pneumoniae isolates from
Taiwan had meropenem MICs of £1 mg/L [11]. In contrast,
isolates producing the NDM metallo-b-lactamase have higher
carbapenem MICs, only 3% of those described having
meropenem MICs of £2 mg/L [12].
A wide variation in carbapenem MICs has also been
observed among KPC-producing K. pneumoniae isolates.
More speciﬁcally, among 42 contemporary KPC-producing
K. pneumoniae isolates from the eastern USA, one had a
meropenem MIC of 1 mg/L, eight had a meropenem MIC
of 2 mg/L, and the remaining 33 had higher MICs [27]. On
the other hand, in a Chinese study, all 95 KPC-producing
K. pneumoniae isolates had carbapenem MICs ranging from
3 to ‡32 mg/L [9]. In our geographical region (Athens,
Greece), the MICs for a signiﬁcant proportion (32%) of
KPC-producing K. pneumoniae isolates remain below 4 mg/L.
Indeed, among 150 contemporary KPC-producing K. pneu-
moniae blood isolates tested in our laboratory, 41 had
MICs for meropenem of £2 mg/L and seven had MICs of
£1 mg/L (range: 0.12 to ‡32 mg/L). Similar MICs were
observed for imipenem and doripenem (G. L. Daikos,
unpublished data).
Revision of Carbapenem Breakpoints and
Unresolved Issues
Following the evaluation of MIC distributions of contempo-
rary carbapenemase-producing isolates, pharmacokinetic
(PK)/pharmacodynamic (PD) properties, and limited clinical
outcome data, both the EUCAST and the CLSI in the USA
revised their susceptibility breakpoints for carbapenems.
First, the EUCAST decided to set its clinical breakpoints to
£2 mg/L for imipenem and meropenem, £1 mg/L for doripe-
nem, and £0.5 mg/L for ertapenem [28]. More recently, the
CLSI reduced its previous breakpoint values to £1 mg/L for
imipenem, meropenem, and doripenem, and to £0.25 mg/L
for ertapenem [29,30]. Both committees intended the
revised breakpoints to improve the ability of microbiological
laboratories to detect carbapenemase-producing organisms
by routine susceptibility testing without the performance of
additional conﬁrmatory tests, while at the same time obtain-
ing clinically meaningful results to guide physicians in making
decisions on treatment. In these schemes, the presence or
absence of a carbapenemase does not in itself inﬂuence the
categorization of susceptibility, so isolates that produce car-
bapenemases but have MICs below the breakpoints are
reported as tested.
However, even with these recent modiﬁcations of break-
points, several issues remain unresolved. On the one hand, a
proportion of isolates will be reported as susceptible to car-
bapenems, despite the presence of carbapenemases, depend-
ing on the geographical region and the type of
carbapenemase. Thus, a number of patients infected with
such isolates may receive a carbapenem for treatment, a
therapeutic approach that is not considered appropriate by
some experts [20,31]. On the other hand, by lowering the
breakpoints and reporting as resistant a larger proportion of
CPKP isolates, we decrease the opportunities for some
patients to obain the potential therapeutic beneﬁt of carba-
penems. For example, there are carbapenemase-producing
isolates with carbapenem MICs of 4 or 8 mg/L (reported as
resistant on the basis of the revised interpretive criteria) that
cause infections for which there is no other therapeutic
option, or for which the efﬁcacy of alternative treatments
(tigecycline or colistin) is very doubtful [15]. A notable
example is the questionable efﬁcacy of colistin or gentamicin
monotherapy in neutropenic patients [32]. Such therapeutic
dilemmas arise often in areas where carbapenemase-produc-
ing organisms are endemic. In the absence of controlled
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comparative trials, therefore, critical interpretation of data
from animal infection models and PK/PD studies, and contin-
uing appraisal of our clinical experience, may provide selec-
tion criteria for ‘when to give or not to give’ carbapenems in
infections caused by carbapenemase-producing organisms.
Animal Infection Models
Several investigators have examined the efﬁcacy of carbapen-
ems against CPKP isolates in animal infection models [33–35]
(Craig et al., 48th ICAAC, 2008, Abstract A-029). Daikos
et al. [33] assessed the activity of imipenem against VIM-1-
producing K. pneumoniae (VPKP) isolates in the neutropenic
murine thigh infection model. Animals were infected with
three VPKP isolates (with imipenem MICs of 2, 4 and 32 mg/
L, respectively) and a susceptible clinical isolate (MIC of
0.125 mg/L) that did not produce any b-lactamase with
broad-spectrum activity. The bactericidal effect was greatest
against the susceptible non-VIM-1-producing isolate, inter-
mediate against the ‘susceptible’ VPKP isolates (imipenem
MICs of 2 and 4 mg/L), and minimal against the resistant VPKP
isolate (imipenem MIC of 32 mg/L). With administration of
higher doses of imipenem and attainment of a drug exposure
of approximately 40% time above MIC (T > MIC) an apprecia-
ble effect against the VIM-1-producing isolates with low imipe-
nem MICs (2–4 mg/L) was achieved. Similar results were
obtained by Souli et al. [34] in a rabbit model of peritoneal
abscess, using a carbapenem-susceptible (meropenem MIC of
1 mg/L) VIM-producing Escherichia coli isolate as the infecting
organism; carbapenems produced a statistically signiﬁcant
reduction of bacterial colony forming units as compared with
the untreated controls, and this reduction was comparable to
that achieved by aztreonam, to which the infecting organism
was susceptible. More importantly, the mortality rate in the
control group (11 of 16; 68.8%) was higher than that in
the imipenem-treated group (ﬁve of 15; 33.3%, p 0.003), the
meropenem-treated group (two of 15; 13.3%, p 0.003), the
ertapenem-treated group (three of 16; 18.8%, p 0.01), and
the aztreonam-treated group (0 of 15; p <0.001). Comparison
of mortality rates among treatment groups did not yield any sta-
tistically signiﬁcant differences. Both of these studies therefore
suggest the utility of carbapenems against VIM-1-producing
organisms with carbapenem MICs up to 4 mg/L.
In animal infection models, the time for which free carba-
penem remains above the MIC (as a percentage of the dos-
ing interval, %T > MIC) must be 20–30% for bacteriostatic
activity and 40–50% for bactericidal activity [36]. Craig et al.
(48th ICAAC, 2008, Abstract A-029), using the mouse thigh
infection model, compared the activity of carbapenems
against wild-type Enterobacteriaceae and strains with KPC
exhibiting carbapenem MICs between 1 and 16 mg/L. The
authors demonstrated that the presence of KPC in Entero-
bacteriaceae had no impact on the PD (%T > MIC) necessary
for bacteriostasis by imipenem, meropenem, or doripenem.
Similarly, in an in vitro model simulating human pharmaco-
kinetics, Bulik et al. [37] showed that a high dose of merope-
nem (2 g every 8 h) infused over 3 h was bactericidal against
KPC-producing K. pneumoniae isolates with MICs of 2 mg/L.
Although the targeted 40% T > MIC exposure was achieved
by this dosing regimen against KPC-producing K. pneumoniae
isolates with meropenem MICs up to 16 mg/L, this drug was
not able to produce a reliable reduction in the bacterial den-
sity in two of three KPC-producing K. pneumoniae isolates
with MICs of 8 mg/L.
In another study, the same group of investigators evalu-
ated the efﬁcacy of 1-g and 2-g doses, and prolonged infu-
sions, of doripenem against KPC-producing K. pneumoniae
isolates with MICs ranging from 4 to 32 mg/L, in both immu-
nocompetent and neutropenic mice [35]. The 1-g dose was
able to produce only a bacteriostatic response for the KPC-
producing K. pneumoniae isolates with MICs of 4 and 8 mg/L,
whereas the 2-g dose achieved a similar effect for isolates
with MICs up to 16 mg/L. Relative to neutropenic mice, in
the immunocompetent animals a signiﬁcant reduction in bac-
terial density was observed, with overall decreases of up to
1 log, with either the 1-g or the 2-g doripenem dose. A criti-
cal interpretation of the animal infection model data just
summarized suggests that high-dose, prolonged-infusion regi-
mens of carbapenems are able to achieve at least a bacterio-
static effect in severely compromised hosts and a modest
bactericidal effect in immunocompetent animals infected with
KPC-producing K. pneumoniae isolates with MICs up to
8 mg/L. Moreover, Bulik and Nicolau [38], exploiting the high
afﬁnity of the KPC enzyme for ertapenem, demonstrated
that the efﬁcacy of doripenem against KPC-producing
K. pneumoniae isolates is enhanced when it is administered in
combination with ertapenem, suggesting the potential utility
of double-carbapenem therapy against this pathogen.
Outcome of Patients Infected with CPKP
Isolates and Clinical Experience with
Carbapenem Treatment
Clinical experience in the treatment and outcome of patients
infected with CPKP isolates is limited to case reports, case
series, retrospective studies, and one prospective observa-
tional study (Table 1). Several investigators from the USA,
Israel, Taiwan and Greece have reported mortality rates
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ranging from 24% to 65% in patients infected with CPKP iso-
lates [5,10,15,24,25,39]. Resistance to carbapenems, older
age and severity of underlying disease have been shown to
be independent predictors of death in these patients [25,40].
Given that CPKP isolates exhibit an extensive drug-resistant
phenotype, an additional factor contributing to adverse out-
come in these infections may be the delay in initiating appro-
priate empirical therapy.
Over the last ﬁve years, the development of resistance to
colistin and/or tigecycline, the ‘last-resort’ treatments for
these infections, has further compromised the therapeutic
options [19–21]. Currently, in our geographical region,
approximately 20% of CPKP isolates are resistant to colistin,
and 5% of these organisms are pan-drug-resistant, exhibiting
resistance to both colistin and tigecycline. In the absence of
alternative treatments, and in light of the aforementioned
animal model experiments, we therefore need to examine
the utility of carbapenems against CPKP isolates, and particu-
larly against those that have low carbapenem MICs. In order
to address this issue, we performed a search of MEDLINE,
including the terms: carbapenemase-Klebsiella, VIM-Klebsiella,
KPC-Klebsiella, IMP-Klebsiella, and NDM-Klebsiella. We com-
piled data from the published reports that provided the nec-
essary information to examine the efﬁcacy of carbapenems in
relation to carbapenemase production and to the MIC for
the infecting organisms (Table 1). We were able to extract
data from 44 patients infected with CPKP isolates, all of
whom had received carbapenem monotherapy [11,14,22–
25,39,41–43]. Among these patients, 32 were infected with
CPKP isolates for which carbapenem MICs were £4 mg/L,
ﬁve with CPKP isolates for which the MICs were 8 mg/L,
and seven with CPKP isolates organisms for which the MICs
were >8 mg/L. For comparison, we evaluated 22 patients
infected with non-carbapenemase-producing K. pneumoniae
isolates with carbapenem MICs of £0.5 mg/L, all of whom
had received carbapenem monotherapy (data on ﬁle [25]).
By analysing these data, we observed that, for CPKP infec-
tions, the therapeutic efﬁcacy of carbapenems increases from
29% for an MIC of >8 mg/L, to 60% for an MIC of 8 mg/L,
and to 69% for an MIC of 4 mg/L or less. Although the com-
parison between the groups was not statistically signiﬁcant, it
is worth noting that the efﬁcacy of carbapenems in the last
TABLE 1. Clinical studies, antimicrobial therapies and outcomes of patients infected with carbapenemase-producing Klebsiella
pneumoniae
References
First
author (year of
publication)
Study
design
No. of
patients
Carbapenemase
(no. of isolates)
Treatment
(no. of patients)
Outcome (no. of
successes/
no. of failures)
42 Villegas (2004) Case reports 11 KPC (11)
IMP (1)
Carbapenem (4)
Carbapenem combined with another agent (1)
Other treatment (6)
5/6
22 Lomaestro (2006)
43 Wei (2007)
17 Daly (2007)
52 Mendes (2008)
41 Endimiani (2008)
53 Marschall (2009)
14 Mathers (2009)
54 Benenson (2009)
11 Yan (2001) Case series 16 IMP (16) Carbapenem (3)
Other treatment (13)
9/7
39 Lee (2004) Case series 3 IMP (3) Carbapenem (3) 3/0
55 Bradford (2004) Case series 4 KPC (4) Carbapenem combined with another therapy (3)
Other treatment (1)
3/1
10 Bratu (2005) Retrospective 58 KPC (29) No precise information on treatment (58) 9/20
24 Daikos (2007) Retrospective 28 VIM (28) Carbapenem (11)
Carbapenem combined with another agent (13)
Other treatment (4)
9/19
18 Souli (2008) Case series 17 VIM (17) Carbapenem combined with another agent (9)
Other treatment (8)
14/3
23 Weisenberg (2009) Case series 21 KPC (21) Carbapenem (11)
Carbapenem combined with another agent (1)
Other treatment (9)
8/13
56 Maltezou (2010) Case series 22 KPC (22) Carbapenem combined with another agent (1)
Other treatment (13)
No information on treatment (8)
11/3
57 Endimiani (2009) Case series 7 KPC (7) Carbapenem combined with another agent (1)
Other treatment (1)
No information on treatment (5)
4/3
58 Nadkarni (2009) Case series 6 KPC (6) Other treatment 2/4
25 Daikos (2009) Prospective observational 67 VIM (67) Carbapenem (14)
Carbapenem combined with another agent (12)
Other treatment (41)
16/51
59 Souli (2010) Case series 18 KPC (18) Carbapenem (1)
Carbapenem combined with another agent (11)
Other treatment (6)
11/7
15 Mouloudi (2010) Case control 37 VIM (18)
KPC (19)
Other treatment (37) 21/16
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group was similar to that observed in patients infected with
non-carbapenemase-producing K. pneumoniae (73%). In addi-
tion, we analyzed data from 138 patients who had received
appropriate treatment other than carbapenem monotherapy
[15,17,18,23,24,25,58,59]. The lowest mortality rate (only
three of 26 died) was observed among those patients who
received combination therapy with two active drugs, one of
which was a carbapenem (when its MIC was £4 mg/L) and
the other of which was an aminoglycoside (11 patients), or
colistin (14 patients), or tigecycline (one patient), as com-
pared with that observed in patients who received other
active drug(s) besides carbapenems (46 of 112 patients had
adverse outcome; OR 5.3, 95% CI 1.5–18.9, p 0.006, Fisher’s
exact test). These data indicate that carbapenems provide
some therapeutic beneﬁt against CPKP isolates when the
MIC is £4 mg/L. Therefore, for clinical purposes, the carba-
penem MICs should be reported as tested, and the presence
or absence of a carbapenemase should not in itself inﬂuence
the categorization of the isolates as resistant or susceptible.
Human PK and PD Studies
The aforementioned experimental and clinical outcome data
are supported by human PK/PD studies. Carbapenems are
known to display time-dependent bactericidal killing when free
drug concentrations remain above the MIC for approximately
40–50% of the time between dosing intervals. Previous reports
have provided PK data for several dosing regimens of merope-
nem; in particular, the traditional 30-min infusion of 1 g every
8 h (1 g TI every 8 h), the prolonged 3-h infusion of 1 g every
8 h (1 g PI every 8 h), and the high-dose/prolonged 3-h infu-
sion of 2 g every 8 h (2 g PI every 8 h) [36,44–48]. As shown
in Fig. 1, when the traditional 1 g TI every 8 h regimen was
used, the serum meropenem concentration fell below 2 mg/L
(EUCAST breakpoint) 5 h after administration. In contrast,
prolonging the infusion time to 3 h (1 g PI every 8 h) resulted
in serum concentrations above 2 mg/L for the whole time
interval between dosages, which were further increased to
concentrations above 4 mg/L when the meropenem dose was
doubled (2 g PI every 8 h).
Moreover, Monte Carlo simulation models of different
dosing regimens of carbapenems indicate that prolonging the
infusion time from 30 min to 3 h increases the probability of
bactericidal target attainment at each MIC value. As shown
in Fig. 2, the probabilities of attaining T > MIC targets for at
least 50% of the dosing intervals for an MIC of 4 mg/L were
69%, 93% and 100% for the 1 g TI every 8 h, 1 g PI every
8 h and 2 g PI every 8 h dosing regimens, respectively. For
an MIC of 8 mg/L, only the high-dose/prolonged-infusion reg-
imen displayed a relatively high probability (85%) of bacterici-
dal target attainment [36]. Considering these observations in
combination with the MIC distributions of CPKP isolates, the
high-dose/prolonged-infusion regimen of meropenem
achieves the bactericidal PK/PD targets with a high degree of
certainty for carbapenemase-producing Enterobacteriacae that
have MICs of £4 mg/L. An additional factor that should be
taken into consideration is the fact that CPKP isolates affect
mainly critically ill and immunocompromised patients, as
there is evidence that the probability of clinical response as a
function of %T > MIC may be different in this population.
Therefore, it is preferable to use the high-dose/prolonged-
infusion regimen of carbapenems in CPKP infections, in
order to achieve drug exposure for at least 75% T > MIC
[49]. Moreover, depending on the severity of infection and
the immune status of the host, the therapeutic efﬁcacy of
carbapenems against CPKP infections could be enhanced by
adding another active agent, as discussed above. It is
FIG. 1. Simulated concentration–time proﬁles of three different dos-
ing regimens of meropenem. TI, traditional 30-min infusion; PI, pro-
longed 3-h infusion. Adapted from [35,45,47].
FIG. 2. Simulated target attainment probabilities for 50% time above
the MIC (50% T > MIC) of three different regiments of meropenem.
TI, traditional 30-min infusion; PI, prolonged 3-h infusion. Adapted
from [36].
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important to note that, before adopting high-dose and
extended-infusion regimens, consideration should be given to
the safety and stability of the compounds used. For example,
imipenem is not likely to be considered for this therapeutic
strategy, in view of its lower stability at elevated room tem-
peratures and its lower tolerability when administered in
higher dosages [50,51]. In addition, we need to monitor
renal function regularly and adjust the carbapenem dose as
required, particularly for the high-dose regimens, as the
majority of the patients infected with CPKP isolates are criti-
cally ill and have altered renal function.
Conclusion
When faced with the daily challenge of managing critically ill
patients, we should try to reduce the gap between the avail-
able medical evidence for using carbapenems against CPKP
infections and the dearth of alternative therapeutic options,
some of which have not been satisfactorily investigated and/or
whose efﬁcacy in certain situations remains questionable.
Whether we can use carbapenems in the presence of a carba-
penemase is an issue on which divergent opinions have been
expressed by several experts. The data analyses presented
herein support the notion that carbapenems may be a reason-
able treatment option against CPKP, provided that: (i) the
carbapenem MIC for the infecting organism is £4 mg/L; (ii) a
high-dose prolonged-infusion regimen is administered to drive
the PK/PD proﬁle to acceptable exposures; and (iii) this class
of agent is administered in combination with another active
compound. Finally, the data summarized in this review indicate
that the EUCAST clinical breakpoints (susceptible, £2 mg/L;
intermediate, 4 mg/L) can direct physicians in making treat-
ment decisions. In the absence of control trials, the continued
appraisal of clinical experience will provide further important
information on the utility of carbapenems against CPKP.
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